DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Biosimiliar Hotspots.pdf

Where are the Biosimilars Hotspots? 1 biosimilar product has been approved in the united states and there has been a 49% annual increase in biosimilars in clinical trials.